A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma.
Hou J et al. Am J Clin Oncol. 2017 Sep 19. doi: 10.1097/COC.0000000000000404. [Epub ahead of print].

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Cavenagh J et al. Br J Cancer. 2017 Sep 5. doi: 10.1038/bjc.2017.302. [Epub ahead of print].#

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.
Dispenzieri A et al. Bone Marrow Transplant. 2017 Sep 4. doi: 10.1038/bmt.2017.164. [Epub ahead of print].

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/ refractory MM.
Moreau P et al. Blood. 2017 Aug 28. pii: blood-2017-06-788323. doi: 10.1182/blood-2017-06-788323. [Epub ahead of print].